(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

AstraZeneca reported a significant 77% surge in quarterly net profit, reaching $2.53 billion, driven by strong US growth and ...

British pharmaceutical giant AstraZeneca announced surging quarterly profit Thursday on strong sales of cancer drugs and as ...

The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to $15.19 billion from $13.57 billion.

AstraZeneca chief exec Pascal Soriot (pictured) said Britain should be trying to attract cash from the pharmaceutical sector but was pushing it away.